Presentation at European Society of Cardiology Demonstrates VIVO Accuracy in Complex VT Patients
Catheter Precision, Inc. (NYSE American:VTAK) today announced that at the recently held European Society of Cardiology (ESC) Symposium, interim results demonstrating the use of VIVO in localizing the ...
Medpage Today on MSN1d
Reconsider When a Prophylactic ICD Is Needed in Nonischemic Dilated Cardiomyopathy
Better imaging parameters may exist for risk stratification in nonischemic dilated cardiomyopathy (NIDCM), based on a ...
Clinical trial: Preventing heart injury caused by anticancer drugs
The RESILIENCE clinical trial has been designed to explore the effectiveness and safety of remote ischemic conditioning (RIC) ...
bernama9d
Beyond The Three Highs: The Silent Threat Of Obesity In Malaysia
This concerning trend comes alongside the already alarming increase in chronic diseases, rooted in what’s commonly known as ...
The EMBO Journal8d
An intrinsic mechanism of metabolic tuning promotes cardiac resilience to stress
FAO is catalyzed by the mitochondrial trifunctional protein (MTP) and, if overloaded, generates ROS. ROS are boosted during ...
The EMBO Journal3d
Acetylation of TIR domains in the TLR4-Mal-MyD88 complex regulates immune responses in sepsis
Activation of macrophage TLR4 by bacterial endotoxins is important for the progression of sepsis, but the underlying ...
Pharmaceutical Technology12d
CLV-100 by Cytopeutics for Graft Versus Host Disease (GVHD): Likelihood of Approval
CLV-100 is under clinical development by Cytopeutics and currently in Phase II for Graft Versus Host Disease (GVHD).
PharmaEssentia Announces Licensing Agreement with FORUS Therapeutics to Commercialize BESREMi® (ropeginterferon alfa-2b-njft) in Canada
PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and ...